DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report

TJ Wigle, EV Tsvetkova, SA Welch, RB Kim - Pharmaceutics, 2019 - mdpi.com
5-Fluorouracil remains a foundational component of chemotherapy for solid tumour
malignancies. While considered a generally safe and effective chemotherapeutic, 5 …

The past, present, and future of chemotherapy with a focus on individualization of drug dosing

L DeRidder, DA Rubinson, R Langer… - Journal of Controlled …, 2022 - Elsevier
While there have been rapid advances in developing new and more targeted drugs to treat
cancer, much less progress has been made in individualizing dosing. Even though the …

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update

U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

A review of body composition and pharmacokinetics in oncology

JJ Hopkins, MB Sawyer - Expert review of clinical pharmacology, 2017 - Taylor & Francis
Introduction: Body surface area dosing of chemotherapeutic agents is based on limited
scientific data, and often results in unpredictable plasma drug levels. Cross-sectional …

Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices

P Smita, PA Narayan, P Gaurav - Frontiers in Oncology, 2022 - frontiersin.org
Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree
of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to …

Pharmacogenetics of drugs used in the treatment of cancers

B Franczyk, J Rysz, A Gluba-Brzózka - Genes, 2022 - mdpi.com
Pharmacogenomics is based on the understanding of the individual differences in drug use,
the response to drug therapy (efficacy and toxicity), and the mechanisms underlying variable …

In silico models in drug development: where we are

J Piñero, LI Furlong, F Sanz - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•A variety of computational methods and tools are used in QSP and QST. They
show different degrees of maturity.•PBPK models are well established and applied in a wide …

[HTML][HTML] 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer

K Morawska, F Goirand, L Marceau, M Devaux… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Aims 5-FU is used as the main backbone of chemotherapy regimens for patients with
colorectal and other gastrointestinal cancers. Despite development of new strategies that …

Fabrication and use of poly (d, l-lactide-co-glycolide)-based formulations designed for modified release of 5-fluorouracil

N Leelakanok, S Geary, A Salem - Journal of pharmaceutical sciences, 2018 - Elsevier
fluorouracil (5-FU) is a chemotherapeutic agent that has been used for the treatment of a
variety of malignancies since its initial introduction to the clinic in 1957. Owing to its short …

Recent perspectives in hot melt extrusion-based polymeric formulations for drug delivery: applications and innovations

Y Ren, L Mei, L Zhou, G Guo - Aaps Pharmscitech, 2019 - Springer
Hot melt extrusion (HME), a technology which mixing the advantages of solid dispersion
technology and mechanical preparation, is accepted in varied applications in …